Actinium Pharmaceuticals (ATNM) News Today → Biden Nomination CANCELED? (From The Freeport Society) (Ad) Free ATNM Stock Alerts $9.83 +0.10 (+1.03%) (As of 05/16/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartEarningsHeadlinesOwnershipShort InterestStock AnalysisAnalyst ForecastsChartEarningsHeadlinesOwnershipShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 16 at 3:59 PM | marketbeat.comActinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) Sees Significant Growth in Short InterestActinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM - Get Free Report) was the recipient of a large increase in short interest during the month of April. As of April 30th, there was short interest totalling 2,330,000 shares, an increase of 17.7% from the April 15th total of 1,980,000 shares. Based on an average daily trading volume, of 378,800 shares, the short-interest ratio is currently 6.2 days.May 15 at 8:30 AM | prnewswire.comActinium to Host KOL Webinar to Discuss Iomab-ACT Commercial CAR T-Cell Therapy Trial Design, Objectives and Potential Market OpportunityMay 15 at 6:26 AM | americanbankingnews.comStephens Initiates Coverage on Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)May 14 at 11:48 PM | markets.businessinsider.comActinium : Iomab-B Phase 3 Trial Results Show Significant Survival Benefit In High-Risk AML PatientsMay 14 at 9:53 PM | markets.businessinsider.comBuy Rating Affirmed: Actinium Pharmaceuticals’ Clinical Triumphs and Strategic Market PositioningMay 14 at 6:38 PM | prnewswire.comActinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients at the EHA 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the Phase 3 SIERRA TrialMay 14 at 4:52 PM | msn.comStephens & Co. Initiates Coverage of Actinium Pharmaceuticals (ATNM) with Overweight RecommendationMay 14 at 10:24 AM | investorplace.com3 Cheap Biotech Stocks to Buy Now: May 2024May 14 at 8:19 AM | marketbeat.comActinium Pharmaceuticals (NYSEAMERICAN:ATNM) Research Coverage Started at StephensStephens began coverage on shares of Actinium Pharmaceuticals in a research note on Tuesday. They issued an "overweight" rating and a $25.00 target price for the company.May 13 at 8:30 AM | prnewswire.comActinium Announces Multiple Abstracts Highlighting its Antibody Radiation Conjugates Iomab-B and Actimab-A and Novel Linker Technology for Solid Tumors Accepted for Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual MeetingMay 12, 2024 | seekingalpha.comA Strong Buy - Actinium Pharmaceuticals Promising AML Treatment With Targeted RadiotherapiesMay 7, 2024 | prnewswire.comActinium Announces KOL Webinar to Highlight Recently Announced Iomab-ACT Trial with Leading FDA Approved Commercial CAR T-Cell Therapy Being Led by the University of Texas SouthwesternMay 6, 2024 | americanbankingnews.comActinium Pharmaceuticals, Inc. to Post Q2 2024 Earnings of ($0.58) Per Share, B. Riley Forecasts (NYSEAMERICAN:ATNM)May 2, 2024 | msn.comRadiopharma stocks higher as sector welcomes the latest M&A dealMay 2, 2024 | marketbeat.comFY2024 EPS Estimates for Actinium Pharmaceuticals, Inc. Boosted by Analyst (NYSEAMERICAN:ATNM)Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM - Free Report) - Analysts at Cantor Fitzgerald boosted their FY2024 EPS estimates for Actinium Pharmaceuticals in a research note issued to investors on Tuesday, April 30th. Cantor Fitzgerald analyst K. Kluska now anticipates that the biotechnologMay 1, 2024 | tmcnet.comPostman Announces Winners of Inaugural Postman API Network AwardsMay 1, 2024 | finance.yahoo.comPostman Supercharges AI Development with New API Enhancements at POST/CON 2024May 1, 2024 | tmcnet.comSandbox Banking chosen to be API Management and Integration Platform as a Service (iPaaS) provider for new COCC ConnectSuite platformMay 1, 2024 | yahoo.comCitigroup's VC arm invests in API security startup TraceableMay 1, 2024 | marketbeat.comResearch Analysts Set Expectations for Actinium Pharmaceuticals, Inc.'s FY2024 Earnings (NYSEAMERICAN:ATNM)Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM - Free Report) - Equities researchers at HC Wainwright increased their FY2024 earnings estimates for shares of Actinium Pharmaceuticals in a research report issued on Monday, April 29th. HC Wainwright analyst J. Pantginis now forecasts that the biApril 30, 2024 | msn.comOil inventories in surprise inventory build last week: APIApril 30, 2024 | finance.yahoo.comAI, Machine Learning Are the New Battleground for API Exploits, According to New Wallarm ReportApril 30, 2024 | marketbeat.comHC Wainwright Equities Analysts Increase Earnings Estimates for Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM)Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM - Free Report) - Equities research analysts at HC Wainwright upped their FY2026 earnings per share (EPS) estimates for Actinium Pharmaceuticals in a research report issued to clients and investors on Monday, April 29th. HC Wainwright analyst J. PaApril 30, 2024 | msn.comWTW and Riskonnect collaborate to enhance risk management with new API toolApril 29, 2024 | marketbeat.comActinium Pharmaceuticals (NYSEAMERICAN:ATNM) Rating Increased to Hold at StockNews.comStockNews.com raised shares of Actinium Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Monday.April 29, 2024 | marketbeat.comShort Interest in Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) Decreases By 9.6%Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM - Get Free Report) was the target of a large decrease in short interest during the month of April. As of April 15th, there was short interest totalling 1,980,000 shares, a decrease of 9.6% from the March 31st total of 2,190,000 shares. Based on an average trading volume of 354,100 shares, the short-interest ratio is currently 5.6 days.April 29, 2024 | finance.yahoo.comThreatX Unites DevOps and Security Like Never Before With Always-Active API Security From Development to RuntimeApril 29, 2024 | marketbeat.comHC Wainwright Reiterates "Buy" Rating for Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)HC Wainwright restated a "buy" rating and set a $50.00 target price on shares of Actinium Pharmaceuticals in a report on Monday.April 29, 2024 | za.investing.comStandard Bank’s API Marketplace Wins: 2024 Digital CX AwardsApril 27, 2024 | msn.comStainless Aids OpenAI, Anthropic, and Others to Develop API SDKsApril 27, 2024 | msn.comNew Report Complains About API Representation in Entertainment: It's as Whiny as It SoundsApril 26, 2024 | yahoo.comDiddo’s new funding will bring its shoppable TV API to streaming platformsApril 26, 2024 | msn.comThe Bank of London launches GenAI assistant to aid enterprise API integrationApril 26, 2024 | msn.comNew Gen AI Tech Revolutionizes Financial API Usage by Bank of LondonApril 23, 2024 | finance.yahoo.comOrchest Technologies Elevates Connectivity Landscape with API Business Intelligence Integration and Online Hardware Marketplace DebutApril 23, 2024 | finance.yahoo.comGlobal Application Programming Interface (API) Security Markets, Trends, Opportunities, and Forecasts, 2028FApril 22, 2024 | tmcnet.comLEAP Boosts Global Customer Reach with Vonage SIP Trunking API IntegrationApril 20, 2024 | msn.comGoogle is shutting down the PaLM API for most usersApril 18, 2024 | markets.businessinsider.comActinium Says Phase 3 SIERRA Trial Results Of Iomab-B Shows Improving OS For AML PatientsApril 18, 2024 | prnewswire.comActinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual MeetingApril 15, 2024 | investorplace.comBiotech on a Budget: 7 Stocks Under $10 With Huge PotentialApril 12, 2024 | msn.comMeta Welcomes Developers to Threads with Open API DocumentationApril 10, 2024 | venturebeat.comOpenAI makes GPT-4 Turbo with Vision generally available through its APIApril 9, 2024 | tmcnet.comMyCompanyWorks launches EntityMachine™, the Innovative Business Entity Formation and Management APIApril 9, 2024 | 9to5mac.comMeta shares more details on Threads API ahead of June releaseApril 9, 2024 | finance.yahoo.comThe API Innovation Center, Apertus Pharmaceuticals Bring API Production of Critical Generic Cancer Drug to U.S. SoilApril 9, 2024 | finance.yahoo.comGlobal Pharmaceutical CDMO Market Analysis Report 2024-2030: AI-Assisted Drug Active Pharmaceutical Ingredient (API) Synthesis Gaining AttentionApril 9, 2024 | tmcnet.comMEF Pioneers Industry Leading Enterprise Business and Operational LSO API Portfolio for Network ServicesApril 4, 2024 | marketbeat.comFY2024 EPS Estimates for Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) Lifted by Cantor FitzgeraldActinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM - Free Report) - Equities researchers at Cantor Fitzgerald raised their FY2024 earnings estimates for shares of Actinium Pharmaceuticals in a note issued to investors on Monday, April 1st. Cantor Fitzgerald analyst K. Kluska now anticipates that tApril 4, 2024 | stockhouse.comNextdoor Launches Ads API Program, Offering Advertisers an Easier Way to Extend Their Campaigns to Nextdoor Get Actinium Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ATNM and its competitors with MarketBeat's FREE daily newsletter. Email Address Biden replacement revealed? (Ad)A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13. See his shocking evidence in this new report ATNM Media Mentions By Week ATNM Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ATNM News Sentiment▼0.440.55▲Average Medical News Sentiment ATNM News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ATNM Articles This Week▼133▲ATNM Articles Average Week Get Actinium Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ATNM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: NATR News Today ME News Today VTYX News Today CRMD News Today RANI News Today AQST News Today XOMA News Today VNDA News Today NLTX News Today INZY News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSEAMERICAN:ATNM) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersThe 1,000X Crypto PlaybookTrue Market InsidersCrypto Pioneer Says: “The last crypto bull market has begun.”InvestorPlaceWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaMost important medical advance in 100 yearsThe Oxford ClubBill Clinton Backing Biden Replacement???The Freeport SocietyCharles Payne Demystifies OptionsUnstoppable ProsperityWhy Is Gold On a MASSIVE rally? Huge Alerts Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Actinium Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
